Ani Pharmaceuticals (ANIP) Depreciation & Amortization - Total (2012 - 2020)

Ani Pharmaceuticals has disclosed Depreciation & Amortization - Total across 9 years of filings, most recently posting $1.3 million for Q4 2020.

• Depreciation & Amortization - Total for Q4 2020 came in at $1.3 million, up 8.33% year-over-year; the trailing twelve-month figure through Sep 2021 was $1.3 million (down 72.92% YoY), and the FY2025 annual result was $8.9 million, up 20.27% from the prior year.
• Depreciation & Amortization - Total came in at $1.3 million for Q4 2020 at Ani Pharmaceuticals, up from $1.2 million in the prior quarter.
• In the past five years, Depreciation & Amortization - Total ranged from a high of $1.3 million in Q4 2020 to a low of $200000.0 in Q1 2016.
• The 5-year median for Depreciation & Amortization - Total is $500000.0 (2018), against an average of $680000.0.
• Across the five-year window, Depreciation & Amortization - Total changed 0.0% in 2016 and jumped 300.0% in 2019, its largest moves.
• Ani Pharmaceuticals' Depreciation & Amortization - Total stood at $200000.0 in 2016, then surged by 50.0% to $300000.0 in 2017, then soared by 166.67% to $800000.0 in 2018, then surged by 50.0% to $1.2 million in 2019, then gained by 8.33% to $1.3 million in 2020.
• The last three Depreciation & Amortization - Total figures came in at $1.3 million (Q4 2020), $1.2 million (Q3 2020), and $1.2 million (Q2 2020), per Business Quant data.